Skip to main content
Figure 3 | Diabetology & Metabolic Syndrome

Figure 3

From: CNX-013-B2, a unique pan tissue acting rexinoid, modulates several nuclear receptors and controls multiple risk factors of the metabolic syndrome without risk of hypertriglyceridemia, hepatomegaly and body weight gain in animal models

Figure 3

CNX-013-B2 reduces blood glucose and lipid levels. A- Fasting (6 h) glucose in DIO mice. B- Fed glucose in ob/ob mice. C- Fasting TG in DIO mice. D- Fasting TG in ob/ob mice. E- Total cholesterol and F-LDLc. All the values are expressed as Mean ± SEM; one way analysis of variance followed by Dunnett’s test for representing significance value of the treatment groups. P value significance was represented as (*) <0.05, (**) <0.01 and (***) <0.001 when compared with DIO control. (#) <0.05 and (###) <0.001 as compared to lean or ob/+.

Back to article page

Diabetology & Metabolic Syndrome

ISSN: 1758-5996

Contact us